Please ensure Javascript is enabled for purposes of website accessibility

Will Cigarette Companies Save Us From COVID-19?

By Rich Duprey – May 26, 2020 at 12:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Their biotech units are in the race to find a vaccine.

Although there are many companies pursuing a vaccine for COVID-19, the tobacco industry may be one of the more surprising combatants in this battle.

Both British American Tobacco (BTI -1.32%) and Philip Morris International (PM -1.73%) are working on a vaccine for the disease. That's ironic because not only are tobacco companies routinely vilified for the harm to health their primary products cause, but also because smokers have an elevated risk of contracting the coronavirus.

Yet it might be the very nature of their association that could allow them to succeed.

Worker drying tobacco leaves

Image source: Getty Images.

A not-unfamiliar position

Unlike automakers or cosmetics companies converting production facilities to make personal protective equipment, it's not the actual manufacturing units of the tobacco companies working to fight COVID-19, but rather their biotech divisions.

The tobacco giants have formidable biotech units that are actually no stranger in battles against infectious disease. But these operations are perhaps unknown to many investors because they don't take a prominent role in the production of cigarettes.

British American's Kentucky BioProcessing, for example, was instrumental in helping to develop one of the most successful antidotes to the Ebola virus in the Democratic Republic of Congo.

In partnership with Arizona State University and Mapp Biopharmaceutical, Kentucky BioProcessing began "pharming" Mapp's ZMapp drug, which was credited with saving the lives of two U.S. missionaries in Liberia who were infected with Ebola. According to the university, "Within 24 hours after taking ZMapp ... [they] went from death's door to walking again."

Kentucky BioProcessing's role was to grow the ZMapp antidote in a tobacco plant, a process that British American says generates a vaccine faster, taking only a matter of weeks rather than months.

Plant-based alternatives

British American, the owner of cigarette brands including Lucky Strike, Kent, and Pall Mall, is taking a similar approach to its development of a COVID-19 vaccine. Bloomberg reports Kentucky BioProcessing has cloned a portion of the virus' genetic sequence, which led to the production of antibodies that are subsequently being inserted into tobacco plants for production. British American said Kentucky BioProcessing will not be making a profit on a COVID-19 vaccine.

Bloomberg also reported Philip Morris International is similarly working to develop a plant-based vaccine through its own biotech division, Medicago. The company says vaccines developed in plants are not rejected by the body, but instead allow them to develop immune responses while preventing the virus from infecting the body or replicating itself. 

Medicago, named after a plant commonly known as medick, expects to initiate human trials by this summer and submit the drug to regulators for approval by November 2021.

A global commitment

With much of the world still on lockdown and millions of people testing positive for the coronavirus, over 100 companies are moving quickly to develop a COVID-19 vaccine. There is hope that Moderna (MRNA -0.37%), with its mRNA-1273 vaccine, might be one of the first to achieve success.

British American Tobacco's vaccine candidate is ready for human trials, and with Food and Drug Administration approval, those tests could begin next month. While some might consider it the height of irony if a tobacco company were to win the race for a COVID-19 vaccine, even the most optimistic participants don't expect we'll have one before next year.

That means many of the temporary health and safety protocols we've adopted will need to become a more permanent part of our routine. 

Rich Duprey has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Philip Morris International Stock Quote
Philip Morris International
PM
$85.47 (-1.73%) $-1.50
British American Tobacco Stock Quote
British American Tobacco
BTI
$36.55 (-1.32%) $0.49
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$125.15 (-0.37%) $0.47

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
339%
 
S&P 500 Returns
109%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/07/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.